ABCA1 and Splenomegaly: Combination therapy with miglustat, HPßCD and allopregnanolone has largely reduced the development of neurological symptoms (Davidson et al., 2009; Meyer et al., 2017, 2018) and also improved visceral symptoms such as hepato- and splenomegaly, but increased both lipolysis and cholesterol transport via abca1 and apoE (Ebner et al., 2018).